Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Combination vaccines are recommended by health authorities worldwide to reduce the number of jabs given to children while ...

Vaccination is a critical tool in the fight against infectious diseases, but recent findings suggest that where you receive ...

When it comes to vaccines, where they go into your body can make a surprising difference in how well they work. Scientists in ...

To access our most recent research and articles on Covid-19 and Covid-19 vaccines, please visit the NEJM Coronavirus (Covid-19) page. To realize the potential of recently developed Covid-19 ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

The three AGA mouse model groups were treated separately for 18 days as follows: Mock (subcutaneous injection, 0.1 mL/animal, every 3 days); murine EX104 (subcutaneous injection, 0.1 mL/animal, every ...

With an increasing number of subcutaneous drugs available in cancer treatment, oncology nurses are spending more time administering these injections, which can lead to exhaustion and soreness.

The first doses of an FDA-authorized Covid-19 vaccine have been delivered to all 50 states, the District of Columbia and Puerto Rico, a little after a year the disease was first discovered in China, ...